Singular Health Posts $1.43m Revenue with $6.34m Loss in FY26

Revenue Growth Driven by US Commercial Deployments

Singular Health Group (ASX:SHG) posted a striking 507% jump in revenues to $1.43 million for the year ended 30 June 2026, propelled by the commercial deployment of its 3DICOM™ medical imaging platform within the US healthcare market. This surge reflects the company's transition from technology development to revenue generation, highlighted by the receipt of a US$500,000 licence payment from Provider Network Solutions (PNS) following the deployment of 750 3DICOM™ MD® licences across PNS’s primary care network.

Losses Narrow Slightly Despite Increased Investment

Despite the revenue upswing, Singular Health recorded a net loss after tax of $6.34 million, a marginal 1% improvement from the prior year's $6.38 million loss. The operating loss of $6.34 million was driven by increased expenses in research and development, employee costs, and marketing, reflecting continued investment in product commercialisation and organisational capability. Notably, share-based payment expenses fell to $2.09 million from $3.27 million the previous year, partially offsetting higher operating costs.

Regulatory Milestones and Intellectual Property Strengthening

The year saw significant regulatory progress with the FDA granting 510(k) clearance for the browser-based 3DICOM™ MD® Cloud platform, enabling support for a broad range of diagnostic imaging modalities including CT, MRI, PET, X-ray, and ultrasound. The Group maintained compliance with key healthcare security standards such as ISO 27001, HIPAA, and SOC 2 Type II, while advancing towards HITRUST certification to bolster enterprise healthcare customer confidence.

On the intellectual property front, Singular Health secured a favourable patentability opinion from the World Intellectual Property Organization for its Medical File Transfer Protocol (MFTP), facilitating national phase patent filings in multiple jurisdictions including the US, Europe, and Asia. This development significantly fortifies the Group’s global IP portfolio and underpins future commercialisation efforts.

Expansion of US Operations and Acquisition of Control

Singular Health expanded its US footprint by forming new entities in Delaware and Singapore and, notably, acquired control of its associate Singular Imaging Solutions US Inc post-year-end, increasing its stake from 30% to approximately 60%. This acquisition will see SIS-US consolidated as a controlled entity in FY27, with the financial impact yet to be finalised. The move signals a deeper commitment to the US market and integration of operations within the PNS network.

Commercial and Educational Deployments Progress

Beyond PNS, the Group advanced discussions with major US healthcare payers such as Triple-S health plan, aiming to deploy an enterprise imaging platform incorporating its suite of 3DICOM™ solutions. The Life Radiology pilot in Florida enrolled over 230 patients, validating the cloud-based patient imaging platform. The Group also initiated a paid pilot with Miami-Dade County Public Schools, targeting healthcare education applications with student onboarding planned for September 2026.

Financial Position and Capital Management

Singular Health ended FY26 with a robust financial position, holding $2.36 million in cash and $7.7 million in term deposits, down from $13.05 million the prior year, and positive working capital of $10.4 million. The Group raised $1.54 million through option exercises during the year, supporting ongoing investment in product development and commercialisation. The Board affirmed confidence in the Group's ability to fund its operations for at least the next twelve months.

Risks and Strategic Outlook

The Group highlighted key risks including intellectual property protection challenges, dependence on senior personnel, regulatory approvals for new applications, competitive pressures, and data privacy concerns inherent in handling sensitive medical imaging data. The Board remains focused on executing its strategy to become a leading provider of interoperable healthcare imaging infrastructure, leveraging its strengthened US commercial pipeline, regulatory clearances, and expanding enterprise partnerships.